Changes to anti-JCV antibody levels in a Swedish national MS cohort
about
Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert groupIs the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis.Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy.Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathyDetection of circulating hcmv-miR-UL112-3p in patients with glioblastoma, rheumatoid arthritis, diabetes mellitus and healthy controls.Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.Immunological Markers for PML Prediction in MS Patients Treated with NatalizumabJC polyomavirus infection is strongly controlled by human leucocyte antigen class II variantsDiagnostic assays for polyomavirus JC and progressive multifocal leukoencephalopathyThe human JC polyomavirus (JCPyV): virological background and clinical implications.Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards.Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.Natalizumab: risk stratification of individual patients with multiple sclerosis.Current role of chemotherapy and bone marrow transplantation in multiple sclerosis.Immunology of progressive multifocal leukoencephalopathy.Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology.High cumulative JC virus seroconversion rate during long-term use of natalizumab.Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biologicaJohn Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients.Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.Anti-JC virus seroprevalence in a Finnish MS cohort.Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.Anti-JC virus antibodies in rituximab-treated patients with neuromyelitis optica spectrum disorder.Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF.Anti-JC Virus Antibody Prevalence in Canadian MS Patients.JC-virus seroconversion in multiple sclerosis patients receiving natalizumab.Predicting PML in natalizumab-treated patients: can we do better?The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.Anti-JC virus antibody testing for natalizumab-induced progressive multifocal leukoencephalopathy: Where are we and where should we go?
P2860
Q26780412-5AE21A1B-10D1-42BF-ADC1-06E2D5540B56Q33562701-497940DA-02B6-4019-8759-E26087C1E436Q33573208-2D2E5734-9EEF-4002-820D-B71D82DF8E2BQ33693085-67817569-2575-4AA6-A6FD-4860E8D80F1FQ34324861-DB6494A5-536B-4686-8B06-FDA59C8483B8Q34612095-CC3B1F68-C79C-4349-BC39-9F50D8A51A76Q34803324-3464F103-C9E2-4DBF-A082-477953266DABQ34818048-26783D8E-F2EE-4DAF-A56F-6A6874BE8312Q35157207-5E77F802-D959-4207-ABC6-4F3BA66F6F12Q36942417-75549CA1-76B2-4F47-B650-B47B3B89EB84Q38115572-E543F66B-150E-400D-BCD6-EE4C44142763Q38116451-53D7D1FA-676F-451E-A07D-4D9CFE093952Q38172961-6F549603-0C91-4E7F-BDA0-79C066F1E86EQ38221343-97152CAF-0929-49EF-AAFE-C619E97E6CB4Q38268313-59D43E7F-29E1-479C-8EC7-AD9DBCA1CE62Q38367755-687B2838-CF06-4668-950D-9E6724FD18FEQ38558344-05F61B7A-ACAD-424E-88D7-DC0D626B3E6EQ39886328-F69C585A-B2BC-471E-8BFA-578A95EC64D9Q40067748-3BA9057D-E8B2-4135-85BF-7D162009B78CQ40122994-68DE7C8B-585A-4FA8-AF89-C906745EFEFAQ40401876-38148ACD-7E33-46E2-AFBB-8BC919469E19Q40565210-2B4B1EA9-9EBF-4BBB-A4D3-CE4E1549AAA3Q42170814-8D19EE44-5F8F-4EEA-ACA5-0B8560CEAFCCQ42175650-DC4DAA95-FB0C-4839-9CB5-8C3C4477E4EAQ42181572-59613DD0-4093-4592-9482-26BBC688C7C6Q42181998-6C4F03F9-7BFC-4A13-B9EB-02222A08F4E5Q42266414-4B17F52C-6C87-417E-89CE-62B933443C9BQ44495152-3C557D8C-90CC-47D9-B0A7-89B98338A728Q45325710-5DB4B5BB-355D-4426-9547-543AA23EA6A1Q45334987-0F687D3C-47A6-44E7-B02D-8173D7347756
P2860
Changes to anti-JCV antibody levels in a Swedish national MS cohort
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 March 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Changes to anti-JCV antibody levels in a Swedish national MS cohort
@en
Changes to anti-JCV antibody levels in a Swedish national MS cohort.
@nl
type
label
Changes to anti-JCV antibody levels in a Swedish national MS cohort
@en
Changes to anti-JCV antibody levels in a Swedish national MS cohort.
@nl
prefLabel
Changes to anti-JCV antibody levels in a Swedish national MS cohort
@en
Changes to anti-JCV antibody levels in a Swedish national MS cohort.
@nl
P2093
P2860
P50
P356
P1476
Changes to anti-JCV antibody levels in a Swedish national MS cohort
@en
P2093
Afsar Rahbar
Anna Fogdell-Hahn
Carolina Holmén
Clemens Warnke
Jan Hillert
Meena Subramanyam
Susan Goelz
Tatiana Plavina
Tomas Olsson
P2860
P304
P356
10.1136/JNNP-2012-304332
P407
P577
2013-03-05T00:00:00Z